Indications : Relapsed or Refractory B-Cell precursor ALL
Medicine Description : Blincyto is a bispecific T-cell engager (BiTE) therapy for B-cell acute lymphoblastic leukemia (B-ALL). It activates T-cells to attack cancer cells expressing CD19. Given as a continuous IV infusion, it significantly improves remission rates. Side effects include cytokine release syndrome (CRS), neurotoxicity, and fever. Careful monitoring is essential to manage severe immune-related reactions.
Note: The content is from Google and open sources.
Disclaimer:
1. For prescribing information, please contact your physician.
2. Medicine will be procured based on a valid prescription only.
